ALLMedicine™ Waldenstrom Macroglobulinemia Center

Dec 2nd, 2021 - B-cell malignancies represent a diverse collection of diseases and, taken together, make up the majority of hematologic malignancies. B-cell lymphomas represent the largest percentage of these neoplasms, and the relapsed and/or refractory B-cell l...

Nov 12th, 2021 - Waldenström macroglobulinemia (WM) is a rare B-cell lymphoproliferative malignancy. Autologous hematopoietic cell transplantation (auto-HCT) is considered in a subset of WM patients with relapsed disease. While registry data has shown a benefit fo...

Oct 23rd, 2021 - Bing-Neel syndrome (BNS) is a rare syndrome that occurs in patients with Waldenstrom macroglobulinemia and is characterized by lymphoplasmacytic infiltration into the leptomeningeal tissue and/or the central nervous system. It represents an extram...

Sep 18th, 2021 - Herein, we present the final report of a single-center, prospective phase II study evaluating ibrutinib 420 mg once daily in 30 treatment-naive patients with Waldenstrom macroglobulinemia (WM). The present study is registered with ClinicalTrials.G...

Sep 12th, 2021 - BGB-3111, a novel Bruton's tyrosine kinase (BTK) inhibitor, shows promising anti-cancer effects in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), and Waldenstrom macroglobulinemia (WM). This study ai...

Dec 2nd, 2021 - B-cell malignancies represent a diverse collection of diseases and, taken together, make up the majority of hematologic malignancies. B-cell lymphomas represent the largest percentage of these neoplasms, and the relapsed and/or refractory B-cell l...

Aug 26th, 2021 - AT rich interacting domain containing protein 1A (ARID1A) is a tumor suppressor gene frequently mutated in solid tumor malignancies, often loss of function mutations (frameshift or non-sense). ARID1A encodes a large nuclear protein BAF250a, a vita...

Feb 2nd, 2021 - Participants will be asked to complete a medical survey which includes demographics, diagnosis, and treatment history, medical history, lab results and symptoms experienced. Participants will then receive instructions for the tissue banking proced...

Mar 6th, 2015 - OBJECTIVES: Primary To assess the progression-free and overall survival of patients with symptomatic Waldenstrom macroglobulinemia treated with bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin hydrochloride, cyclophosphamide, and eto...

Oct 29th, 2021 - When to initiate treatment is as important as what to use for the treatment of patients newly diagnosed with Waldenstrom macroglobulinemia (WM), a leading expert in the disease emphasizes. "We have to be very careful not to tell patients they have...

Apr 2nd, 2021 - Transcript: Ian W. Flinn, MD, PhD: Let’s get away from BTK inhibitors in Waldenström macroglobulinemia. They’re clearly a really important addition to our armamentarium for this disease. What else excites you? John, is there anything else that...

Apr 2nd, 2021 - Transcript: Ian W. Flinn, MD, PhD: Hello, and thank you for joining us for this OncLive Peer Exchange® titled, Updates in Targeted Therapies for B-Cell Malignancies. I’m joined by a group of my colleagues who are renowned experts in B-cell mal...

Apr 2nd, 2021 - Today- FDA approvals in follicular lymphoma and prostate cancer, a biosimilar approved for several cancers, a new drug application in prostate cancer, results from 2 late-stage prostate cancer trials, and encouraging findings in a chronic lymph...

Apr 2nd, 2021 - Today- An FDA approval in melanoma, priority review designations in acute myeloid leukemia and Waldenstrom macroglobulinemia, new drug applications accepted in melanoma and non-small cell lung cancer, and additions to immunotherapy labels in bl...